Lyell Immunopharma
LYEL
LYEL
118 hedge funds and large institutions have $256M invested in Lyell Immunopharma in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
10% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 30
0.18% more ownership
Funds ownership: 2.44% → 2.62% (+0.18%)
0% more call options, than puts
Call options by funds: $3K | Put options by funds: $3K
Holders
118
Holding in Top 10
4
Calls
$3K
Puts
$3K
Top Buyers
| 1 | +$5.3M | |
| 2 | +$1.81M | |
| 3 | +$1.71M | |
| 4 |
Morgan Stanley
New York
|
+$1.63M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$1.45M |
Top Sellers
| 1 | -$6.41M | |
| 2 | -$6.35M | |
| 3 | -$892K | |
| 4 |
Rafferty Asset Management
New York
|
-$625K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$478K |